FDA’s Zuckerman Warns Against Inventor Involvement In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Inventors should have minimal involvement in early clinical trials of their own technology, according to FDA's top cardiovascular device reviewer
You may also be interested in...
MedPAC Wants Congress To Require Sunshine For Doc/Device Maker Ties
The Medicare Payment Advisory Commission (MedPAC) is recommending to Congress that health care providers be required to report their financial relationships with industry on a public Web site
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.